North American Scientific said that the proceeds from the sale of this product line will provide the company with important non-dilutive capital to invest in ongoing operations.
John Rush, president and CEO of North American Scientific, said: “We have successfully closed this transaction in the expected time frame and we are now focused on the therapeutic areas of our business with our Prospera and ClearPath product lines for local radiation treatment for the prostate and breast cancer patients.”